| Literature DB >> 29750181 |
Yoshitaka Iso1,2, Hiroshi Suzuki3, Etsushi Kyuno2, Atsuo Maeda3, Fumiyoshi Tsunoda2, Ryo Miyazawa4, Hitoshi Kowaita4, Hitomi Kitai4, Tetsuya Takahashi5, Takeyuki Sambe1.
Abstract
Entities:
Year: 2018 PMID: 29750181 PMCID: PMC5941238 DOI: 10.1016/j.ijcha.2018.02.002
Source DB: PubMed Journal: Int J Cardiol Heart Vasc ISSN: 2352-9067
Baseline characteristics.
| Patient characteristics | Lower limb lesion | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gender | Age, yr | DM | HT | DLP | Smoking | CKD | CAD | COPD | ABI rt | ABI lt | CIA | SFA | BK | CLZ | The other anti-PLT drugs | History of RVT | |
| Case 1 | Male | 66 | + | + | + | + | 0.53 | 0.65 | + | + | + | PG | |||||
| Case 2 | Male | 75 | + | + | + | + | 0.47 | 0.69 | + | + | + | AS | |||||
| Case 3 | Female | 70 | + | + | + | 0.85 | 0.63 | + | + | AS, TP | |||||||
| Case 4 | Male | 63 | + | + | + | + | + | + | 0.46 | 0.88 | + | + | + | TP | |||
| Case 5 | Male | 79 | + | + | + | + | 0.78 | 0.6 | + | + | + | TP | + | ||||
| Case 6 | Female | 67 | + | + | + | 0.86 | 0.66 | + | + | + | + | ||||||
| Male 4 (67%) | 68.5 | 4 (67%) | 6 (100%) | 4 (67%) | 4 (67%) | 2 (33%) | 3 (50%) | 1 (17%) | 0.66 | 0.66 | 3 (50%) | 5 (83%) | 6 (100%) | 4 (67%) | NA | 1 (17%) | |
DM, diabetes mellitus. HT, hypertension. DLP, dyslipidemia. CKD, chronic kidney disease. CAD, coronary artery disease. COPD, chronic obstructive pulmonary disease. ABI, ankle-brachial index. IA, iliac artery. SFA, superficial femoral artery. BK, below knee arteries. CLZ, cilostazol. PLT, platelet. PG, oral prostaglandin E1 derivative. AS, aspirin. TP, thienopyridine. RVT, revascularization therapy.
Age and ABI were expressed as medians.
Changes of CPX parameters.
| CPX parameters | Baseline | Follow-up | |
|---|---|---|---|
| RMR (ml/min/kg) | 3.3 (2.9–4.1) | 3.5 (3.0–4.2) | 0.63 |
| AT (ml/min/kg) | 9.7 (7.8–12.7) | 10.4 (8.4–13.8) | 0.09 |
| Peak VO2 (ml/min/kg) | 12.6 (11.3–15.8) | 14.5 (11.7–16.6) | 0.03 |
| VE/VCO2 slope | 36.0 (34.7–38.6) | 36.3 (29.2–42.8) | 1 |
| Peak WR (watt) | 58 (54–83) | 69.5 (62–88) | 0.03 |
| Cycling time ( | 329 (276–483) | 404 (303–513) | 0.03 |
RMR, resting metabolic rate. AT, anaerobic threshold. WR, work rate.
All data were expressed as medians (range). The non-parametric Wilcoxon signed-rank test was used to assess the changes in CPX parameters between the pre- and post-CR program. P values of <0.05 were considered significant.